Imipramine Pamoate
Brand Names: Tofranil-PM
Methodology & AI Transparency ⓘ
Imipramine Pamoate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Imipramine Pamoate (75 mg/1 Capsule and 125 mg/1 Capsule; NDC 0054-0273, 0054-0275) as a oral-route tricyclic antidepressant formulation manufactured/labeled by Hikma Pharmaceuticals USA Inc when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: 92% patient "Worth It" rating across 17 anonymous logs for Imipramine Pamoate (RxNorm 835591).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $75.44 wholesale mail-order against $184.83 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Imipramine Pamoate include nausea (9.3%), headache (7.5%), dizziness (5.3%).
Ask our AI Specialists anything about Imipramine Pamoate
Imipramine Pamoate Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Imipramine Pamoate (75 mg/1 Capsule and 125 mg/1 Capsule; NDC 0054-0273, 0054-0275) as a oral-route tricyclic antidepressant formulation manufactured/labeled by Hikma Pharmaceuticals USA Inc when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Imipramine Pamoate exerts selective tricyclic antidepressant pharmacodynamic activity across 75 mg/1 Capsule and 125 mg/1 Capsule (oral-route route, manufactured/labeled by Hikma Pharmaceuticals USA Inc), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 0054-0273, 0054-0275).
Systemic exposure to Imipramine Pamoate reflects Estimated 63%–75% oral systemic absorption for Imipramine Pamoate absorption kinetics and phase i/ii hepatic conjugation of imipramine pamoate coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 6–15 hours terminal plasma half-life for Imipramine Pamoate half-life window (peak plasma concentration (tmax) reached 1–2 hours post-dose for imipramine pamoate response profile).
Dosing protocols (75 mg/1 Capsule or 125 mg/1 Capsule or 150 mg/1 Capsule or 100 mg/1 Capsule or 100mg Capsule) balance efficacy (92.00% patient satisfaction across 17 logs) against nausea (9.3% of reports), headache (7.5% of reports), fatigue (5.5% of reports), with strict avoidance in prior anaphylaxis, angioedema, or severe hypersensitivity to imipramine pamoate or imipramine pamoate excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 imipramine pamoate spl.
Avoid overlapping tricyclic antidepressant prescriptions alongside Imipramine Pamoate to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Imipramine Pamoate maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Imipramine Pamoate or Imipramine Pamoate excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Imipramine Pamoate SPL
Logged Side-Effect Incidence (17 Reports)
Imipramine Pamoate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Imipramine Pamoate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| When Antidepressants Aren't Enough: Can Adding SAMe Help Lift Stubborn Depression? SAMe may provide relief of depression symptoms similar to imipramine or escitalopram. General hospital psychiatry • 2024-01-15 • Meta-Analysis | N = 1,522 | 99/100 | PMID 38199136 ↗ |
| New Insights on Effect of concurrent anxiety on response to sertraline and imipramine in patients: What a 426-Participant Study Found Despite the chronicity of depressive illness, acute treatment with both sertraline and imipramine significantly improved psychosocial and quality of life measures. Depression and anxiety • 2001-01-15 • Randomized Controlled Trial | N = 426 | 93/100 | PMID 11233456 ↗ |
| Can This Approach Help? Inside the Latest Research on Gold-standard blind switch study of imipramine or sertraline treatment of More than 50% of chronically depressed antidepressant nonresponders benefited from a switch from imipramine to sertraline, or vice versa, despite a high degree of chronicity. Archives of general psychiatry • 2002-03-15 • Randomized Controlled Trial | N = 117 | 88/100 | PMID 11879161 ↗ |
| Sertraline vs. Imipramine to prevent relapse: Which Works Better for Chronic depression? Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain full symptom relief during 16 weeks of continuation treatment. Journal of affective disorders • 2001-06-15 • Randomized Controlled Trial | N = 147 | 88/100 | PMID 11426506 ↗ |
Imipramine Pamoate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.0066/unit (~$90.20/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $75.44 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $184.83 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $86.76 / mo | View logs ↓ |
Imipramine Pamoate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Imipramine Pamoate RxNorm Concept ID | 835591 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.0066 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $184.83 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $75.44 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 92.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Imipramine Pamoate Patient Community, Cohort Filters & Dosage Logs
Deterministic Imipramine Pamoate reference combining NIH RxNorm (835591), Medicaid NADAC ($3.0066/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Imipramine Pamoate community threads and patient logs by age, biological sex, dosage, and treatment duration.